Here are five key notes on the new facility:
1. The new facility is based on existing high-tech capability and expertise at the site in drug-device combination products for the coronary business. Around 100 professionals from other parts of Medtronic’s business will be stationed at the new facility.
2. The new professionals joining the facility specialize in quality and manufacturing engineering, supply chain and production management.
3. There is 20,000 square feet of space in the facility, with 8,000 square feet dedicated to manufacturing. The facility is designed specifically for manufacturing processes associated with the IN.PACT Admiral drug-coated balloon.
4. The facility cost is expected to be around 13 million Euros.
5. Medtronic finalized it’s acquisition of Ireland-based Covidien at the beginning of this year and the company continues to see synergies since then. The IN.PACT Admiral DCB was launched in the United States on Jan. 5, 2015, a week after the merger, and Medtronic leveraged the combined sales force to bring the product to market faster.
More articles on orthopedic devices:
13 spine devices receive FDA 510(k) clearance in November
Google and Johnson & Johnson to form new surgical company—4 highlights
Fiagon partners with joimax: 4 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
